Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apixaban - Bristol-Myers Squibb/Pfizer

Drug Profile

Apixaban - Bristol-Myers Squibb/Pfizer

Alternative Names: BMS-562247; BMS-562247-01; Eliquis

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Massachusetts General Hospital; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules; Vascular disorder therapies
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Phase III Acute coronary syndromes
  • Phase II Heparin-induced thrombocytopenia and thrombosis syndrome

Most Recent Events

  • 31 Jul 2022 Bristol-Myers Squibb completes enrolment in the phase III AXADIA trial in Stroke and Thromboembolism (in patients with Atrial fibrillation and End-Stage Kidney Disease) in Germany (PO) (NCT02933697)
  • 24 Feb 2022 Phase-III clinical trials in Thromboembolism (In adolescents, In children, In infants, Prevention) in USA (PO) (Bristol Myers Squibb pipeline, February 2022)
  • 11 Jan 2022 Bristol-Myers Squibb initiates an expanded access program of Apixaban in Thromboembolism (In infants, In neonates, In children, In adolescents, Prevention)(NCT05187286)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top